Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 November 2025 | Story Precious Shamase | Photo Supplied
Zandile Mncube
Dr Zandile Mncube presenting her research at the International Mountain Conference (IMC2025) at the University of Innsbruck, Austria.

In a remarkable milestone for both her academic and personal journey, Dr Zandile Mncube, a 27-year-old newly conferred PhD graduate from the University of the Free State (UFS), recently presented her research at the prestigious International Mountain Conference (IMC2025), hosted by the University of Innsbruck, Austria. The event marked not only her debut on the global research stage but also her first international trip and first flight – an experience she described as transformative. 

 

A mountain of research: From UFS weather stations to the global stage

Dr Mncube's journey to this international platform began with encouragement from Prof Ralph Clark, Director of the Afromontane Research Unit, and Dr Melissa Hansen, Lecturer in the Department of Geography, who recognised her potential and urged her to submit an abstract to the conference. 

"Prof Clark proposed that I write an abstract for this conference," Dr Mncube explained. “I had been managing the UFS weather stations and had just begun using their data, so I based my abstract on that work.” 

Her submission was accepted, earning her the opportunity to showcase her research alongside an impressive array of global scholars. The IMC2025, held biennially, brings together experts from across the world to discuss diverse aspects of mountain studies. Dr Mncube formed part of a strong South African delegation that included two students from UFS and one from the University of Cape Town (UCT).

"It was inspiring to see how diverse and multidisciplinary the field is," she said. "It was good to see that, as South Africans, we do fit into the global research stage and can hold our own through the quality of our work.”  

 

Vision for the future: expanding research horizons 

Having been part of the UFS community since 2017 - serving in various roles from student assistant to her current practical and research position – Dr Mncube is now looking ahead to further her research career.

"I want to explore more on the research side of things," she shared. “While I’ve gained valuable experience that could lead to lecturing, my immediate goal is to deepen my involvement in research and fieldwork within Geography.”   

 

A transformative experience and a call for greater support

Describing her participation at the IMC as a "transformative experience, both professionally and personally," Dr Mncube reflected on how it broadened her understanding of global scientific collaboration and highlighted the vital contribution of African researchers. 

She noted there remain "notable gaps in data and contextual understanding that African researchers are uniquely positioned to address," particularly in underrepresented mountain regions.

Dr Mncube strongly advocates for more South African students to be supported in attending international conferences. She observed that several of her peers at the IMC had earned recognition through the Southern African Mountain Conference 2025 (SAMC), further illustrating the value of regional and international engagement. 

"If more students are supported to attend conferences like IMC, it could open doors for them to engage in global research and collaborations that extend far beyond our borders," she said. 

Expressing her heartfelt appreciation, she concluded by thanking Prof Clark and Dr Hansen for their guidance and support, which made her international debut possible.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept